[Effect of sulfinpyrazone on enhanced platelet aggregation in vitro (author's transl)].
Adding sulfinpyrazone in a concentration of 500 and 250 microgram/ml to blood of patients with enhanced platelet stickiness a significant decrease (p less than 0.01) of the maximum amplitude and the aggregation velocity could be demonstrated with the spontaneous platelet aggregation test, PAT III, of Breddin, as well as with the collagen and the ristocetin induced aggregation. The lower concentration of 50 microgram/ml of sulfinpyrazone yielded the same results when aggregation was induced with the higher concentrations of 1.5 microgram/ml ristocetin and 5 microgram/ml collagen. Only the maximum aggregation velocity of the PAT III was significantly reduced after addition of 50 microgram sulfinpyrazone/ml blood. With sufficient concentrations of sulfinpyrazone the anti-aggregating action of this substance can very well be demonstrated with the aggregation induced by ristocetin or collagen and the PAT III. The effect is dose dependent.
D000368:Aged; D003094:Collagen / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D012310:Ristocetin / Q000494:pharmacology; D013442:Sulfinpyrazone / Q000494:pharmacology*
D012310:Ristocetin; D003094:Collagen; D013442:Sulfinpyrazone
Wirkung von Sulfinpyrazon in vitro auf die gesteigerte Thrombozytenaggregation.